| scholarly article | Q13442814 |
| P50 | author | Susan M. Ramin | Q110252023 |
| P2093 | author name string | Yang Xia | |
| Yujin Zhang | |||
| Rodney E Kellems | |||
| Roxanna A Irani | |||
| Sean C Blackwell | |||
| Cissy Chenyi Zhou | |||
| P2860 | cites work | Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? | Q24561702 |
| Complement C3 activation is required for antiphospholipid antibody-induced fetal loss | Q33340713 | ||
| Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset | Q33561285 | ||
| Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome | Q33630007 | ||
| Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | Q33748680 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Fetal nutrition and adult disease | Q33900856 | ||
| Megakaryocytes in the yolk sac, liver and bone marrow of the mouse: a cytometrical analysis by semithin light microscopy | Q34083115 | ||
| US birth weight/gestational age-specific neonatal mortality: 1995-1997 rates for whites, hispanics, and blacks | Q34406757 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Comparative developmental anatomy of the murine and human definitive placentae. | Q34546263 | ||
| The placenta in pre-eclampsia and intrauterine growth restriction | Q34798287 | ||
| Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia | Q35079406 | ||
| For debate: Fetal and early postnatal growth restriction lead to diabetes, the metabolic syndrome and renal failure. | Q35162950 | ||
| Thyroid-stimulating hormone receptor and its role in Graves' disease | Q35599869 | ||
| Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall | Q35787199 | ||
| Apoptosis in the trophoblast--role of apoptosis in placental morphogenesis | Q35879137 | ||
| Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury | Q36007691 | ||
| Apoptosis and its role in the trophoblast | Q36437226 | ||
| The role of RAS in the pathogenesis of preeclampsia | Q36467563 | ||
| Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation | Q36468176 | ||
| The role of the immune system in preeclampsia | Q36791219 | ||
| The functional role of the renin-angiotensin system in pregnancy and preeclampsia | Q37039872 | ||
| Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? | Q37366512 | ||
| Intrauterine growth restriction: implications for placental metabolism and transport. A review. | Q37368571 | ||
| Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants | Q37377636 | ||
| Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats | Q37449704 | ||
| Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation | Q40735093 | ||
| Activity and protein expression of Na+/K+ ATPase are reduced in microvillous syncytiotrophoblast plasma membranes isolated from pregnancies complicated by intrauterine growth restriction | Q42442507 | ||
| Na(+)-K(+)-ATPase is distributed to microvillous and basal membrane of the syncytiotrophoblast in human placenta | Q42490651 | ||
| Establishment and Characterization of First Trimester Human Trophoblast Cells with Extended Lifespan | Q42804803 | ||
| Losartan and fetal toxic effects | Q43531337 | ||
| Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway | Q43982318 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| Role of reactive oxygen species in endothelin-induced hypertension | Q44521159 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Fetal growth restriction: a workshop report. | Q45079728 | ||
| Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia | Q46305789 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. | Q46362446 | ||
| Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. | Q47909651 | ||
| Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia | Q47915288 | ||
| Fetal growth and placental function. | Q52184966 | ||
| Divergent trophoblast invasion and apoptosis in placental bed spiral arteries from pregnancies complicated by maternal anemia and early-onset preeclampsia/intrauterine growth restriction | Q61865458 | ||
| Relationship between antiphospholipid antibodies and recurrent fetal loss in patients with systemic lupus erythematosus and apparently healthy women | Q69725519 | ||
| Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen | Q71695937 | ||
| Fetal outcome in women with primary Sjögren's syndrome. A retrospective case-control study | Q72295495 | ||
| Fetal origins of cardiovascular disease | Q73134554 | ||
| Placental apoptosis in preeclampsia | Q74047219 | ||
| Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy | Q74090763 | ||
| Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in preeclampsia | Q74195115 | ||
| In utero programming of chronic disease | Q74813945 | ||
| An essential role for angiotensin II type 1a receptor in pregnancy-associated hypertension with intrauterine growth retardation | Q75197234 | ||
| Intrauterine growth restriction and reduced glomerular number: role of apoptosis | Q79161073 | ||
| Angiotensin II decreases system A amino acid transporter activity in human placental villous fragments through AT1 receptor activation | Q79760387 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autoantibody | Q785022 |
| intrauterine growth restriction | Q1671598 | ||
| pre-eclampsia | Q61335 | ||
| P304 | page(s) | 2809-2822 | |
| P577 | publication date | 2009-11-02 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia | |
| P478 | volume | 206 |
| Q38126570 | A complicated role for the renin-angiotensin system during pregnancy: highlighting the importance of drug discovery |
| Q27003069 | A leading role for the immune system in the pathophysiology of preeclampsia |
| Q34870775 | A2B adenosine receptor-mediated induction of IL-6 promotes CKD. |
| Q38118625 | Activating autoantibodies and cardiovascular disease |
| Q36039299 | Angiotensin II revisited: new roles in inflammation, immunology and aging |
| Q38859507 | Angiotensin II type 1 receptor antibodies in childhood kidney transplantation |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q43939628 | Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction |
| Q37816496 | Animal models of pre-eclampsia. |
| Q35715914 | Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia |
| Q36050771 | Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling |
| Q34040357 | Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia |
| Q37699015 | Characterization of antibody specificities associated with preeclampsia |
| Q34731047 | Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia |
| Q33740993 | Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia |
| Q38543831 | Linking the old and new -- do angiotensin II type 1 receptor antibodies provide the missing link in the pathophysiology of preeclampsia? |
| Q35053657 | Maternal treatment with agonistic autoantibodies against type-1 angiotensin II receptor in late pregnancy increases apoptosis of myocardial cells and myocardial susceptibility to ischemia-reperfusion injury in offspring rats |
| Q46212939 | Maternal-Fetal rejection reactions are unconstrained in preeclamptic women |
| Q38705264 | Preeclampsia As Modulator of Offspring Health |
| Q39136791 | Recent Advances in Immunity and Hypertension |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q35743816 | Renin angiotensin signaling in normal pregnancy and preeclampsia |
| Q64907090 | Renin-angiotensin system in pre-eclampsia: everything old is new again. |
| Q33783531 | Role of biomarkers in early detection of preeclampsia |
| Q37042332 | Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia |
| Q34169819 | Targeted expression of Cre recombinase provokes placental-specific DNA recombination in transgenic mice |
| Q33672325 | Telmisartan suppresses cardiac hypertrophy by inhibiting cardiomyocyte apoptosis via the NFAT/ANP/BNP signaling pathway |
| Q39385098 | The effects of Nrf2 deletion on placental morphology and exchange capacity in the mouse |
| Q38014802 | The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms |
| Q33755392 | The placenta: transcriptional, epigenetic, and physiological integration during development |
| Q35591704 | The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia. |
| Q57150158 | The role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia |
| Q37240779 | Transglutaminase is a Critical Link Between Inflammation and Hypertension |
| Q86564354 | Transplantation: Autoantibodies-epiphenomena or biological clues |
| Q51294484 | Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension. |
Search more.